Iranian government spokesman Ali Rabiei hinted at the likely response when he said that Tehran “can confidently predict that diplomatic initiatives will work well [to achieve] the desired outcome,” adding that the “diplomatic back-and-forths” are “the natural prelude to the return of all sides to commitments including the lifting of all sanctions in the near future.” If his statements reflect Tehran’s official position, then Iran evidently doesn’t intent to await the results of its presidential election in June, but is willing to begin talks now to exploit the momentum Biden has created.
While it was unclear whether the Iranians would agree to join discussions, three people familiar with the internal debate said it was likely Iran would accept. The officials said Iran would probably be more open to a meeting with the European Union, where the United States was a guest or observer, rather than direct formal talks with Washington as a participant.
Everyone can see what a serious emergency this is. We have to act. Bin the bureaucracy, and get this miracle vaccine to work right now.
The collaboration aims to bring to patients the potential vaccine known as ChAdOx1 nCoV-19, being developed by the Jenner Institute and Oxford Vaccine Group, at the University of Oxford. Under the agreement, AstraZeneca would be responsible for development and worldwide manufacturing and distribution of the vaccine.
The hope in Downing Street is that the Oxford vaccine will get the green light by the end of the year. This would allow the Prime Minister to start laying out plans for restrictions to be lifted.
The MHRA drugs regulator has been doing its final review of the vaccine for three weeks now, since November 27, with a decision expected by next Tuesday.
However, they made a decision about Pfizer and BioNTech’s jab within 10 days of being instructed to do so by the Department of Health.
Sarah Gilbert was at home at the start of the year when she received her first inkling of the perplexing new disease that within months would make her one of the best-known scientists on the planet………..
County clerk Cathy M. Garrett declined to give a specific time frame on when we can expect it to be completed.
“Because of how large our county is, I don’t want to be boxed in with that. But just know that we’re not in a competition.“
Work began on the Oxford vaccine in January. Called AZD1222 or ChAdOx1 nCoV-19, the viral vector vaccine is made from a weakened version of a common cold virus that causes infections in chimpanzees.
AstraZeneca paused its trial in early September to review safety data because a British trial participant developed a neurological condition.
Last week, the Food and Drug Administration authorized the resumption of the company’s U.S. trials after reviewing global safety data. The trial had already resumed in other countries.
“It is encouraging to see immunogenicity responses were similar between older and younger adults and that reactogenicity was lower in older adults, where the COVID-19 disease severity is higher,” an AstraZeneca spokesman told CNBC via email.
“The results further build the body of evidence for the safety and immunogenicity of AZD1222,” the spokesman said, referring to the technical name of the Oxford-AstraZeneca vaccine.